Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate

Azra Hussaini, Anthony J. Olszanski, Cy A. Stein, Bill Bosch, Paul Nemeth

Open source

DOI
10.1007/s00280-017-3360-3
Published
2017-07-10
Container
Cancer Chemotherapy and Pharmacology
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s00280-017-3360-3,
  title = {Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate},
  author = {Azra Hussaini and Anthony J. Olszanski and Cy A. Stein and Bill Bosch and Paul Nemeth},
  year = {2017},
  journal = {Cancer Chemotherapy and Pharmacology},
  doi = {10.1007/s00280-017-3360-3},
  url = {https://doi.org/10.1007/s00280-017-3360-3}
}

RIS

TY  - JOUR
TI  - Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate
AU  - Azra Hussaini
AU  - Anthony J. Olszanski
AU  - Cy A. Stein
AU  - Bill Bosch
AU  - Paul Nemeth
PY  - 2017
JO  - Cancer Chemotherapy and Pharmacology
DO  - 10.1007/s00280-017-3360-3
UR  - https://doi.org/10.1007/s00280-017-3360-3
ER  - 

APA

Hussaini, A., Olszanski, A. J., Stein, C. A., Bosch, B., & Nemeth, P. (2017). Impact of an alternative steroid on the relative bioavailability and bioequivalence of a novel versus the originator formulation of abiraterone acetate. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-017-3360-3

Source records